Welcome to our dedicated page for HeartSciences SEC filings (Ticker: HSCSW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding HeartSciences’ SEC paperwork can feel daunting when R&D costs, FDA pathways, and AI-ECG patent details span hundreds of pages. If you have ever wondered, “How do I find HeartSciences insider trading Form 4 transactions before the market reacts?” this page is built for you.
Stock Titan’s AI engine reads every HeartSciences quarterly earnings report 10-Q filing, Form 4 insider transactions real-time, and 8-K updates on clinical milestones, then translates the legal jargon into plain language bullet points. Need a snapshot of dilution risk? Our tool surfaces equity raises the moment they hit EDGAR. Curious about executive pay? The system links directly to the HeartSciences proxy statement executive compensation tables while our AI highlights performance metrics.
Whether you are tracking HeartSciences earnings report filing analysis for revenue from AI-ECG licenses or seeking HeartSciences annual report 10-K simplified to understand cash runway, you will find every document in one place—updated the second it posts. Use our expert summaries for understanding HeartSciences SEC documents with AI, monitor HeartSciences executive stock transactions Form 4, or get HeartSciences 8-K material events explained so you never miss a regulatory update. Complex filings, made clear.
HeartSciences Inc. (Nasdaq: HSCS) filed Prospectus Supplement No. 3 to update its at-the-market (ATM) program with Maxim Group. The Third Amendment to the September 2023 Equity Distribution Agreement lifts the program’s ceiling to $25 million; however, because the company’s non-affiliate public float is only $13.0 million, General Instruction I.B.6 of Form S-3 caps the immediate raise at $14,737,609. To date, 530,057 shares have been sold for ≈$10.4 million.
Maxim will earn a 4.0 % commission on gross proceeds up to $11.0 million and 3.0 % thereafter. The ATM will terminate upon sale of all registered shares, or may be ended at any time by either party. Shares will be offered “at-the-market” on Nasdaq; the last reported price on 31-Jul-2025 was $3.12 per share, while IPO warrants (HSCSW) traded at $0.1184.
The filing notes that no securities have been sold under I.B.6 limitations in the preceding 12 months. If HeartSciences’ public float exceeds $75 million, Form S-3 restrictions will fall away, enabling larger primary offerings. Investors are reminded to review the company’s risk factors incorporated by reference from its latest 10-K and 10-Q.
HeartSciences Inc. (HSCSW) – Form 144 filing
The notice covers a planned sale of 4,416 common shares through The Charles Schwab Corporation, expected on 29 Jul 2025 on NASDAQ. Based on the disclosed aggregate market value of $15,720.96, the implied price is roughly $3.56 per share. The stock was originally purchased on 08 Dec 2014 from the issuer. No other sales by the filer have occurred in the past three months, and the filer affirms no knowledge of undisclosed adverse information.
The issuer reports 1,934,280 shares outstanding, so the proposed sale equals about 0.23 % of outstanding stock. The form supplies no name or relationship of the seller, indicating only routine compliance with Rule 144 rather than a strategic shift. No financial performance data, guidance changes, or operational updates accompany the filing.
FAQ
What is the current stock price of HeartSciences (HSCSW)?
